6th Annual Anti-Cancer Drug Discovery & Development Summit (CS300)
|Event Date/Time: Jul 21, 2004||End Date/Time: Jul 23, 2004|
|Registration Date: Jul 21, 2004|
|Early Registration Date: Jun 04, 2004|
As renewed hope for better success have emerged from the use of molecular biology to identify unique attributes of tumor cells that can be targeted as drug candidates, numerous agents are now in various stages of development. The finest group of oncology experts has been assembled at this meeting to address the most promising therapeutics including molecular targeted agents, antibodies, vascular targeting and more. Join high-level industrial cancer researchers and business development personnel worldwide at this widely attended conference.
Cancer Therapy – A Proposal
Philip Frost, M.D., Ph.D.
Oncology Research, Wyeth
Approaches against Acquired Capabilities of Tumors & Iressa Update
Jeffrey H. Hanke, Ph.D.,
VP, Cancer Research, AstraZeneca R&D Boston
Discovery & Development Of Kinase Inhibitors For Cancer Treatment
Patrick M. O’Connor, Ph.D.
Vice President of Oncology/Diabetes/Obesity, Pfizer Global R&D
Mapping Molecular Networks: Protein Microarray Analysis of Human Cancer
Emanuel F. Petricoin, Ph.D.
Co-Director, NCI-FDA Clinical Proteomics Program
Senior Principal Investigator, OCGT/CBER/FDA
VEGF Trap: A Novel High-Affinity VEGF Blocker with Potent Anti-Tumor Effects
George D. Yancopoulos M.D., Ph.D.
President of the Laboratories & Chief Scientific Officer, Regeneron Pharmaceuticals, Inc.
Surrogate Markers to Determine Optimal Biologic Dose For Metronomic Chemotherapy and Other Antiangiogenic Drugs
Robert S. Kerbel, Ph.D.
Canada Research Chair in Molecular Medicine
Senior Scientist, Sunnybrook and Women's College Health Sciences Centre
Professor, Departments of Medical Biophysics, University of Toronto
Cancer Immunotherapy: Progress in Cancer Vaccine Development
Robert Hershberg, M.D., Ph.D.
SVP & Chief Medical Officer, Dendreon Corp.
For more information, visit: www.srinstitute.com/cs300.